Concepts (216)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sepsis | 6 | 2023 | 279 | 0.920 |
Why?
|
| Invasive Pulmonary Aspergillosis | 1 | 2021 | 5 | 0.730 |
Why?
|
| Toll-Like Receptor 4 | 3 | 2013 | 344 | 0.700 |
Why?
|
| Hypoxia | 3 | 2024 | 113 | 0.550 |
Why?
|
| Shock, Septic | 3 | 2025 | 86 | 0.540 |
Why?
|
| Intensive Care Units | 7 | 2025 | 405 | 0.520 |
Why?
|
| Respiratory Insufficiency | 4 | 2024 | 154 | 0.510 |
Why?
|
| Sugar Phosphates | 2 | 2013 | 3 | 0.470 |
Why?
|
| Disaccharides | 2 | 2013 | 10 | 0.470 |
Why?
|
| Hospital Mortality | 4 | 2021 | 865 | 0.410 |
Why?
|
| Cannula | 2 | 2024 | 26 | 0.400 |
Why?
|
| Multiple Organ Failure | 2 | 2025 | 43 | 0.380 |
Why?
|
| Respiration, Artificial | 6 | 2021 | 295 | 0.370 |
Why?
|
| Noninvasive Ventilation | 2 | 2024 | 70 | 0.370 |
Why?
|
| Lipid A | 1 | 2010 | 66 | 0.320 |
Why?
|
| Integrins | 4 | 1997 | 109 | 0.300 |
Why?
|
| Double-Blind Method | 8 | 2024 | 739 | 0.300 |
Why?
|
| Bacterial Infections | 1 | 2010 | 148 | 0.290 |
Why?
|
| Lipopolysaccharides | 1 | 2011 | 644 | 0.290 |
Why?
|
| Mucoproteins | 2 | 1997 | 4 | 0.260 |
Why?
|
| Receptors, Lymphocyte Homing | 2 | 1997 | 15 | 0.260 |
Why?
|
| Immunoglobulins | 2 | 1997 | 77 | 0.250 |
Why?
|
| Critical Care | 4 | 2017 | 389 | 0.240 |
Why?
|
| Oxazines | 1 | 2024 | 13 | 0.230 |
Why?
|
| Endotoxins | 1 | 2025 | 80 | 0.230 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 2004 | 36 | 0.230 |
Why?
|
| Morpholines | 1 | 2024 | 89 | 0.230 |
Why?
|
| Pregnancy Complications, Cardiovascular | 1 | 2004 | 33 | 0.220 |
Why?
|
| Pyridines | 1 | 2024 | 111 | 0.220 |
Why?
|
| Adult | 18 | 2025 | 16629 | 0.220 |
Why?
|
| Guideline Adherence | 2 | 2021 | 306 | 0.210 |
Why?
|
| Propensity Score | 1 | 2024 | 154 | 0.210 |
Why?
|
| Clinical Trials as Topic | 3 | 2019 | 453 | 0.210 |
Why?
|
| Humans | 30 | 2025 | 62682 | 0.200 |
Why?
|
| Aged | 15 | 2025 | 14254 | 0.200 |
Why?
|
| Middle Aged | 16 | 2025 | 17365 | 0.190 |
Why?
|
| Male | 19 | 2025 | 29487 | 0.190 |
Why?
|
| Female | 20 | 2025 | 32495 | 0.180 |
Why?
|
| Ventilator-Induced Lung Injury | 1 | 2021 | 10 | 0.180 |
Why?
|
| Hydroxychloroquine | 1 | 2020 | 21 | 0.170 |
Why?
|
| Blood Gas Analysis | 2 | 2017 | 34 | 0.170 |
Why?
|
| Tidal Volume | 2 | 2019 | 41 | 0.170 |
Why?
|
| Acute Chest Syndrome | 1 | 2017 | 4 | 0.140 |
Why?
|
| Blood Substitutes | 1 | 2017 | 5 | 0.140 |
Why?
|
| Patient Safety | 1 | 2020 | 242 | 0.140 |
Why?
|
| Integrin beta Chains | 1 | 1997 | 2 | 0.140 |
Why?
|
| Treatment Outcome | 6 | 2024 | 5591 | 0.140 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 2017 | 44 | 0.140 |
Why?
|
| Protein C | 2 | 2008 | 26 | 0.140 |
Why?
|
| Hemoglobins | 1 | 2017 | 135 | 0.130 |
Why?
|
| Prospective Studies | 4 | 2025 | 3258 | 0.130 |
Why?
|
| Thiamine Deficiency | 1 | 2016 | 8 | 0.130 |
Why?
|
| Thiamine | 1 | 2016 | 21 | 0.120 |
Why?
|
| Protein Structure, Tertiary | 1 | 1997 | 670 | 0.120 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2021 | 708 | 0.120 |
Why?
|
| Lactic Acid | 1 | 2016 | 75 | 0.120 |
Why?
|
| APACHE | 3 | 2010 | 45 | 0.120 |
Why?
|
| Cohort Studies | 3 | 2024 | 2540 | 0.120 |
Why?
|
| Shock | 1 | 2015 | 33 | 0.120 |
Why?
|
| Fluid Therapy | 1 | 2015 | 49 | 0.110 |
Why?
|
| Emergency Service, Hospital | 2 | 2024 | 1070 | 0.110 |
Why?
|
| Lymphocytes | 1 | 1994 | 200 | 0.100 |
Why?
|
| Infusions, Intravenous | 2 | 2010 | 173 | 0.100 |
Why?
|
| Severity of Illness Index | 4 | 2021 | 1541 | 0.090 |
Why?
|
| Gram-Positive Bacteria | 1 | 2011 | 36 | 0.090 |
Why?
|
| Gram-Negative Bacteria | 1 | 2011 | 57 | 0.090 |
Why?
|
| United States | 5 | 2021 | 7721 | 0.090 |
Why?
|
| Phospholipids | 1 | 2011 | 81 | 0.090 |
Why?
|
| Organ Dysfunction Scores | 2 | 2025 | 23 | 0.090 |
Why?
|
| Maximum Tolerated Dose | 1 | 2010 | 40 | 0.080 |
Why?
|
| Acute Disease | 2 | 2024 | 670 | 0.080 |
Why?
|
| Follow-Up Studies | 2 | 2019 | 2445 | 0.080 |
Why?
|
| Renal Dialysis | 1 | 2011 | 197 | 0.080 |
Why?
|
| Antibodies, Neutralizing | 1 | 2011 | 207 | 0.080 |
Why?
|
| Drug Administration Schedule | 1 | 2010 | 299 | 0.080 |
Why?
|
| Choriocarcinoma | 1 | 2008 | 3 | 0.080 |
Why?
|
| Critical Illness | 2 | 2010 | 321 | 0.070 |
Why?
|
| Drug Therapy, Computer-Assisted | 1 | 2008 | 11 | 0.070 |
Why?
|
| Survival Analysis | 1 | 2010 | 576 | 0.070 |
Why?
|
| Uterine Neoplasms | 1 | 2008 | 33 | 0.070 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2008 | 68 | 0.070 |
Why?
|
| Incidence | 2 | 2019 | 1367 | 0.070 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2010 | 862 | 0.070 |
Why?
|
| Cell Adhesion Molecules | 3 | 1997 | 89 | 0.070 |
Why?
|
| Aged, 80 and over | 4 | 2025 | 5403 | 0.070 |
Why?
|
| Blood Glucose | 1 | 2008 | 485 | 0.060 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2005 | 44 | 0.060 |
Why?
|
| Treatment Failure | 2 | 2020 | 198 | 0.060 |
Why?
|
| Pyridazines | 1 | 2024 | 8 | 0.060 |
Why?
|
| Insulin | 1 | 2008 | 687 | 0.060 |
Why?
|
| Anticoagulants | 1 | 2008 | 494 | 0.050 |
Why?
|
| Retrospective Studies | 3 | 2024 | 6533 | 0.050 |
Why?
|
| Pyrimidines | 1 | 2024 | 135 | 0.050 |
Why?
|
| Polymyxin B | 1 | 2023 | 9 | 0.050 |
Why?
|
| Adaptive Clinical Trials as Topic | 1 | 2023 | 5 | 0.050 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2005 | 208 | 0.050 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 2024 | 57 | 0.050 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2024 | 187 | 0.050 |
Why?
|
| Bayes Theorem | 1 | 2023 | 119 | 0.050 |
Why?
|
| Pulmonary Circulation | 1 | 2003 | 26 | 0.050 |
Why?
|
| Pilot Projects | 2 | 2017 | 989 | 0.050 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2023 | 73 | 0.050 |
Why?
|
| Risk Assessment | 1 | 2010 | 2040 | 0.050 |
Why?
|
| Immunosuppressive Agents | 1 | 2004 | 376 | 0.050 |
Why?
|
| Tumor Cells, Cultured | 3 | 1997 | 456 | 0.050 |
Why?
|
| Hemodynamics | 1 | 2003 | 242 | 0.050 |
Why?
|
| Neuromuscular Blockade | 1 | 2021 | 8 | 0.050 |
Why?
|
| Early Medical Intervention | 1 | 2021 | 20 | 0.050 |
Why?
|
| Prone Position | 1 | 2021 | 28 | 0.050 |
Why?
|
| Positive-Pressure Respiration | 1 | 2021 | 48 | 0.040 |
Why?
|
| Vasodilator Agents | 1 | 2021 | 67 | 0.040 |
Why?
|
| Leukemia, Erythroblastic, Acute | 2 | 1997 | 7 | 0.040 |
Why?
|
| HIV Infections | 1 | 2008 | 962 | 0.040 |
Why?
|
| Patient Positioning | 1 | 2021 | 48 | 0.040 |
Why?
|
| Signal Transduction | 1 | 2011 | 3022 | 0.040 |
Why?
|
| Heart | 1 | 2003 | 282 | 0.040 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2023 | 233 | 0.040 |
Why?
|
| Research Design | 1 | 2023 | 572 | 0.040 |
Why?
|
| Cell Adhesion | 3 | 1997 | 207 | 0.040 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2021 | 58 | 0.040 |
Why?
|
| Prognosis | 1 | 2004 | 1724 | 0.040 |
Why?
|
| HLA-DR Antigens | 1 | 2019 | 26 | 0.040 |
Why?
|
| Glucocorticoids | 1 | 2021 | 188 | 0.040 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2019 | 59 | 0.040 |
Why?
|
| Recombinant Fusion Proteins | 2 | 1997 | 495 | 0.040 |
Why?
|
| Transfection | 2 | 1997 | 691 | 0.040 |
Why?
|
| Intubation, Intratracheal | 1 | 2020 | 202 | 0.040 |
Why?
|
| Immunologic Factors | 1 | 2019 | 104 | 0.040 |
Why?
|
| Microvilli | 1 | 1997 | 5 | 0.040 |
Why?
|
| Drug Evaluation | 1 | 2017 | 19 | 0.040 |
Why?
|
| Methemoglobinemia | 1 | 2017 | 8 | 0.040 |
Why?
|
| Jehovah's Witnesses | 1 | 2017 | 18 | 0.040 |
Why?
|
| Lung | 1 | 2003 | 939 | 0.040 |
Why?
|
| Placebos | 1 | 2017 | 71 | 0.040 |
Why?
|
| Treatment Refusal | 1 | 2017 | 55 | 0.030 |
Why?
|
| Epitope Mapping | 1 | 1997 | 50 | 0.030 |
Why?
|
| North America | 1 | 2017 | 111 | 0.030 |
Why?
|
| Cations | 1 | 1997 | 64 | 0.030 |
Why?
|
| Oximetry | 1 | 2017 | 48 | 0.030 |
Why?
|
| Hospitalization | 1 | 2024 | 1344 | 0.030 |
Why?
|
| Pregnancy | 1 | 2004 | 2318 | 0.030 |
Why?
|
| Leukocytes | 1 | 1997 | 103 | 0.030 |
Why?
|
| Serine | 1 | 1997 | 91 | 0.030 |
Why?
|
| Erythrocyte Transfusion | 1 | 2017 | 72 | 0.030 |
Why?
|
| Quality of Health Care | 1 | 2021 | 517 | 0.030 |
Why?
|
| Cattle | 1 | 2017 | 308 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2021 | 725 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2019 | 562 | 0.030 |
Why?
|
| Survival Rate | 1 | 2019 | 839 | 0.030 |
Why?
|
| Data Interpretation, Statistical | 1 | 2017 | 192 | 0.030 |
Why?
|
| Structure-Activity Relationship | 1 | 1997 | 369 | 0.030 |
Why?
|
| Cross Infection | 1 | 2017 | 160 | 0.030 |
Why?
|
| Ligands | 1 | 1997 | 417 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 2 | 1997 | 866 | 0.030 |
Why?
|
| Young Adult | 2 | 2017 | 4633 | 0.030 |
Why?
|
| Central Venous Pressure | 1 | 2015 | 14 | 0.030 |
Why?
|
| Water-Electrolyte Balance | 1 | 2015 | 17 | 0.030 |
Why?
|
| Furosemide | 1 | 2015 | 21 | 0.030 |
Why?
|
| Diuretics | 1 | 2015 | 63 | 0.030 |
Why?
|
| Animals | 4 | 2017 | 20584 | 0.030 |
Why?
|
| Pneumonia | 1 | 2017 | 288 | 0.030 |
Why?
|
| Random Allocation | 1 | 2015 | 197 | 0.030 |
Why?
|
| Manganese | 1 | 1994 | 24 | 0.030 |
Why?
|
| Leukocyte Common Antigens | 1 | 1994 | 59 | 0.030 |
Why?
|
| Integrin beta1 | 1 | 1994 | 32 | 0.030 |
Why?
|
| Risk Factors | 1 | 2004 | 5303 | 0.030 |
Why?
|
| Polymers | 1 | 2017 | 322 | 0.030 |
Why?
|
| Clinical Protocols | 1 | 2015 | 138 | 0.030 |
Why?
|
| Biomarkers | 1 | 2019 | 1385 | 0.030 |
Why?
|
| Molecular Sequence Data | 1 | 1997 | 1992 | 0.030 |
Why?
|
| Cell Line | 2 | 1997 | 2038 | 0.030 |
Why?
|
| Rats | 1 | 1997 | 1978 | 0.030 |
Why?
|
| Protein Binding | 1 | 1997 | 1601 | 0.030 |
Why?
|
| Intestines | 1 | 1993 | 166 | 0.020 |
Why?
|
| Hypertension | 1 | 2017 | 590 | 0.020 |
Why?
|
| Mice | 2 | 1997 | 10804 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2013 | 416 | 0.020 |
Why?
|
| T-Lymphocyte Subsets | 1 | 1993 | 248 | 0.020 |
Why?
|
| Immunologic Memory | 1 | 1993 | 290 | 0.020 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 1993 | 641 | 0.020 |
Why?
|
| Chorionic Gonadotropin, beta Subunit, Human | 1 | 2008 | 3 | 0.020 |
Why?
|
| Respiratory Dead Space | 1 | 2008 | 2 | 0.020 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2008 | 15 | 0.020 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2008 | 61 | 0.020 |
Why?
|
| Viral Load | 1 | 2008 | 229 | 0.020 |
Why?
|
| Interleukin-6 | 1 | 2008 | 319 | 0.020 |
Why?
|
| Point-of-Care Systems | 1 | 2008 | 131 | 0.020 |
Why?
|
| Recurrence | 1 | 2008 | 634 | 0.020 |
Why?
|
| Decision Support Techniques | 1 | 2008 | 194 | 0.020 |
Why?
|
| Drug Costs | 1 | 2005 | 56 | 0.020 |
Why?
|
| Software | 1 | 2008 | 381 | 0.010 |
Why?
|
| Muscles | 1 | 1984 | 179 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2008 | 1638 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2005 | 700 | 0.010 |
Why?
|
| Vascular Capacitance | 1 | 2003 | 2 | 0.010 |
Why?
|
| Cardiac Volume | 1 | 2003 | 7 | 0.010 |
Why?
|
| Ventricular Function | 1 | 2003 | 22 | 0.010 |
Why?
|
| Ventricular Pressure | 1 | 2003 | 30 | 0.010 |
Why?
|
| Patient Selection | 1 | 2005 | 482 | 0.010 |
Why?
|
| Vascular Resistance | 1 | 2003 | 48 | 0.010 |
Why?
|
| Diastole | 1 | 2003 | 92 | 0.010 |
Why?
|
| HIV-1 | 1 | 2008 | 716 | 0.010 |
Why?
|
| Adolescent | 1 | 2013 | 6172 | 0.010 |
Why?
|
| Microscopy, Immunoelectron | 1 | 1997 | 31 | 0.010 |
Why?
|
| Lymphocyte Function-Associated Antigen-1 | 1 | 1997 | 14 | 0.010 |
Why?
|
| Macrophage-1 Antigen | 1 | 1997 | 31 | 0.010 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 1997 | 62 | 0.010 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 1997 | 247 | 0.010 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 1993 | 15 | 0.010 |
Why?
|
| Fibronectins | 1 | 1993 | 43 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 1993 | 2154 | 0.000 |
Why?
|
| Rhodamines | 1 | 1984 | 20 | 0.000 |
Why?
|
| Glycerol | 1 | 1984 | 32 | 0.000 |
Why?
|
| Muscle Relaxation | 1 | 1984 | 32 | 0.000 |
Why?
|
| Rabbits | 1 | 1984 | 332 | 0.000 |
Why?
|
| Models, Biological | 1 | 1984 | 1180 | 0.000 |
Why?
|